Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist for Chronic Weight Management and Type 2 Diabetes

Objectives

•Understand the mechanism of action of Mounjaro, a once-weekly, first-in-class GIP and GLP-1 receptor agonist for chronic weight management and type 2 diabetes.
•Review the efficacy and safety of Mounjaro in chronic weight management and type 2 diabetes.
•Review the efficacy superiority of Tirzepatide compared with Semaglutide in chronic weight management.
•Discuss the safe and effective use of Mounjaro.

This Course For :

Clinical Pharmacy
Pharmacy

Speaker

Provided by :

Price

Course Fee

FREE

FREE
See Registration Policies, Cancellations & Refunds

Contact Information

Organization : Virtual Medical Academy
Phone : 920008161
Email : [email protected]

  • 15 Sep 2025    To    15 Sep 2025
  • 07:00 PM  To  09:00 PM
  • Certificate Available
  • Online
  • 57
  Add to Calendar 09/15/2025 07:00 PM 09/15/2025 09:00 PM Asia/ Riyadh Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist for Chronic Weight Management and Type 2 Diabetes Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist for Chronic Weight Management and Type 2 Diabetes https://medicalacademy.org/portal/event/view/2450
Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist for Chronic Weight Management and Type 2 Diabetes